Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes

Sabrina Lyngbye Wendt, Ajenthen Ranjan, Jan Kloppenborg Møller, Signe Schmidt, Carsten Boye Knudsen, Jens Juul Holst, Sten Madsbad, Henrik Madsen, Kirsten Nørgaard, John Bagterp Jørgensen

Research output: Contribution to conferencePosterResearch

351 Downloads (Pure)

Abstract

Currently, no consensus exists on a model describing endogenous glucose production (EGP) as a function of glucagon concentrations. Reliable simulations to determine
the glucagon dose preventing or treating hypoglycemia or to tune a dual-hormone artificial pancreas control algorithm need a validated glucoregulatory model including the effect of glucagon.
Original languageEnglish
Publication date2017
Number of pages1
Publication statusPublished - 2017
EventAdvanced Technology and Treatments for Diabetes 2017 - Paris, France
Duration: 15 Feb 201718 Feb 2017

Conference

ConferenceAdvanced Technology and Treatments for Diabetes 2017
CountryFrance
CityParis
Period15/02/201718/02/2017

Fingerprint Dive into the research topics of 'Validation of a Simulation Model Describing the Glucose-Insulin-Glucagon Pharmacodynamics in Patients with Type 1 Diabetes'. Together they form a unique fingerprint.

Cite this